FDA head calls for investigation into approval of Biogen Alzheimer’s drug
The acting head of the Food and Drug Administration on Friday called for a government investigation into highly unusual contacts between some of her agency’s drug reviewers and the maker of a controversial new Alzheimer’s drug.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed